Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America

• मुख्य लेखकों: CH Spencer (लेखक), K Rouster-Stevens (लेखक), H Gewanter (लेखक), G Syverson (लेखक), R Modica (लेखक), K Schmidt (लेखक), H Emery (लेखक), C Wallace (लेखक), S Grevich (लेखक), K Nanda (लेखक), YD Zhao (लेखक), S Shenoi (लेखक), S Tarvin (लेखक), S Hong (लेखक), C Lindsley (लेखक), JE Weiss (लेखक), M Passo (लेखक), K Ede (लेखक), A Brown (लेखक), K Ardalan (लेखक), W Bernal (लेखक), ML Stoll (लेखक), B Lang (लेखक), R Carrasco (लेखक), C Agaiar (लेखक), L Feller (लेखक), H Bukulmez (लेखक), R Vehe (लेखक), H Kim (लेखक), H Schmeling (लेखक), D Gerstbacher (लेखक), M Hoeltzel (लेखक), B Eberhard (लेखक), R Sundel (लेखक), S Kim (लेखक), AM Huber (लेखक), A Patwardhan (लेखक), Pediatric Rheumatologist Collaborators (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: BMC, 2017-06-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Abstract Background The prognosis of children with juvenile dermatomyositis (JDM) has improved remarkably since the 1960's with the use of corticosteroid and immunosuppressive therapy. Yet there remain a minority of children who have refractory disease. Since 2003 the sporadic use of biologics...